Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer

Aghaei, Atena; Ayati, Narjess; Shafiei, Susan; Abbasi, Bita

doi:10.1097/mnm.0000000000000730

Cited by 5 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, there have been many reports comparing the efficacy of low versus high RAI activity in patients with DTC; however, the optimal radioactivity remains cont roversial. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] A recent meta-analysis demonstrated that the ablation rate with high RAI activity therapy was better than that with low radioactivity therapy in patients with DTC. 14,15 In contrast, most published studies have shown that low RAI activity was as effective as higher radioactivity in terms of response to therapy.…”

Section: Discussionmentioning

confidence: 99%

Effect of therapeutic radioiodine activity on ablation response in differentiated thyroid cancer patients with cut-off serum thyroglobulin levels after 2 weeks of thyroid hormone withdrawal: a retrospective study

2022

View full text Add to dashboard Cite

This retrospective study aimed to investigate whether there was a difference in the success rate of removal of residual thyroid tissue in patients with the same cutoff serum thyroglobulin (Tg) value―measured 2 weeks after thyroid hormone withdrawal (THW)―for different radioactive iodine (RAI) activities. We identified 132 patients with papillary thyroid cancer who were treated with total thyroidectomy and RAI therapy to evaluate the efficacy of three radioactivities of I-131: 1,110, 3,700, and 5,550 MBq. Serum Tg testing was performed 1 week before RAI treatment and 2 weeks after THW (pre-Tg); the cutoff pre-Tg level was below 10 ng/mL. Stimulated Tg levels were measured on the day of I-131 administration (off-Tg). After 6 months of treatment, we compared the groups for complete ablation, defined as no uptake on a diagnostic I-131 scan, stimulated Tg level of <1.0 ng/mL, and Tg antibody level of <100 ng/mL. Ninety-five patients (72.0%) achieved complete ablation, with 57.1% (8/14), 78.2% (68/87), and 61.3% (19/31) in the 1,110 MBq, 3,700 MBq, and 5,550 MBq groups, respectively. There was no significant difference in the complete ablation rates between the three groups. In the multivariate analysis, the off-Tg level was a significant predictor of complete ablation. RAI therapy with low radioactivity (1,110 MBq) seemed sufficient for ablation in patients with papillary thyroid cancer with a pre-Tg level below 10 ng/mL. The off-Tg level is a promising and useful predictor of complete ablation after initial RAI therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of therapeutic radioiodine activity on ablation response in differentiated thyroid cancer patients with cut-off serum thyroglobulin levels after 2 weeks of thyroid hormone withdrawal: a retrospective study

2022

View full text Add to dashboard Cite

show abstract

“…Several studies suggest that the results of the thyroid remnant ablation and the response to therapy did not differ significantly between low-and high-dose groups in the treatment of low-or intermediate-risk patients with DTC. [29][30][31][32] We also calculated factors associated with successful ablation in FVPTC patients. The data indicated that all factors were similar among successful and unsuccessful ablation groups, including sex, risk level, primary nodule size, Tg level, presence of lymph node metastasis, multiple focal malignant nodule, bilateral malignant nodule, and extrathyroidal extension before RAI for low-to intermediate-risk FVPTC patients.…”

Section: Discussionmentioning

confidence: 99%

Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma

Gray

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

Objectives Follicular variant papillary thyroid carcinoma (FVPTC) is treated similarly to classical variant papillary thyroid carcinoma (cPTC). However, FVPTC has unique tumour features and behaviours. We investigated whether a low dose of radioiodine was as effective as a high dose for remnant ablation in patients with FVPTC and evaluated the recurrence of low-intermediate risk FVPTC. Methods Data from cPTC and FVPTC patients treated with I-131 from 2004 to 2014 were reviewed. Demographics, tumour behaviour, lymph node metastasis, and local recurrence data were compared between FVPTC and cPTC patients. Then, low-intermediate risk FVPTC patients were divided into low, intermediate, and high I-131 dose groups, and postoperative I-131 activities were analysed to evaluate the effectiveness of I-131 therapy for thyroid remnant ablation. Results In total, 799 cases of FVPTC (n = 168) and cPTC (n = 631) treated with I-131 were identified. Patients with FVPTC had a larger primary nodule size than cPTC, but lymph node metastases and local recurrence were more prevalent in cPTC than in FVPTC. For the low-, intermediate-, and high-dose groups, success rates of ablation did not differ (82.0%, 80%, and 81.3%, respectively). Conclusion FVPTC differs from cPTC in behaviour. Low-dose ablation may be sufficient in FVPTC patients with low-intermediate disease risk.

show abstract

“…Erhöhte Raten an zweiten ablativen Radioiodtherapien in den Behandlungsarmen mit 1,1 GBq I-131 fanden sich in 3 weiteren randomisierten Studien, die differente Ablationsaktivitäten verglichen (6,11,19). In einer weiteren Studie mit einem Vergleich von 1,1 GBq versus 5,5 GBq I-131 war nicht die Therapieaktivität, sondern der Thyreoglobulin (Tg)-Spiegel vor der Ablation entscheidend für das spätere Tg-basierte Therapieansprechen (3). Die Nicht-Unterlegenheit von 1,1 GBq versus 3,0 GBq I-131 zeigte eine kleinere koreanische Studie mit Fokus auf Tumorstadien mit einer mikroskopischen extrathyreoidalen Infiltration und mit einer nodalen Metastasierung in das zervikozentrale Kompartiment (pT1a) (37).…”

Section: Standardisierung Bei Der I-131 Aktivitätsreduktionunclassified

Ablative Radioiodtherapie des Schilddrüsenkarzinoms

Dietlein¹,

Drzezga²

2018

Nuklearmedizin

View full text Add to dashboard Cite

show abstract

Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer

Cited by 5 publications

References 29 publications

Effect of therapeutic radioiodine activity on ablation response in differentiated thyroid cancer patients with cut-off serum thyroglobulin levels after 2 weeks of thyroid hormone withdrawal: a retrospective study

Effect of therapeutic radioiodine activity on ablation response in differentiated thyroid cancer patients with cut-off serum thyroglobulin levels after 2 weeks of thyroid hormone withdrawal: a retrospective study

Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma

Ablative Radioiodtherapie des Schilddrüsenkarzinoms

Contact Info

Product

Resources

About